Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C

摘要: Background/Aims: The role of interferon alfa treatment in improving morbidity endpoints patients with chronic hepatitis C infection is currently under debate. aim this study was to evaluate the effectiveness preventing hepatocellular carcinoma and decompensation cirrhosis type C. Methods: A retrospective cohort carried out on 329 consecutive Caucasian followed for a mean period 5 years at seven tertiary care university hospitals. Inclusion criteria were biopsy-proven cirrhosis, anti-HCV positivity, abnormal serum aminotransferase levels absence complications cirrhosis. Results: yearly incidence 2.3% 136 untreated 1.0% 193 treated alfa. hepatic 5.7 1.5 patients. Fourteen (7%) showed sustained normalization none them developed At enrollment, older had more severe liver disease than interferon. After adjustment clinical serologic differences entry between patients, 5-year estimated probability occurrence 2.1% 2.7% 7% 11% cases, respectively. Conclusions: This analysis did not detect any significant benefit compensated C, although it suggests reduction those response therapy, indicates need better therapies.